Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to PET ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Epidemiologic trends of and factors associated with overall survival for patients with gastroenteropancreatic neuroendocrine tumors in the United States.JAMA Netw Open. 2021; 4: e2124750
- The 2019 WHO classification of tumours of the digestive system.Histopathology. 2020; 76: 182-188
- Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).Clin Diabetes Endocrinol. 2018; 4: 16
- Gastroenteropancreatic neuroendocrine tumors.CA Cancer J Clin. 2018; 68: 471-487
- Neuroendocrine cancer, therapeutic strategies in G3 cancers.Digestion. 2017; 95: 109-114
- Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation.Radiographics. 2015; 35: 500-516
- GEP–NETs Update: radionuclide therapy in neuroendocrine tumours.Eur J Endocrinol. 2015; 172: R1-R8
- Phase 3 trial of 177Lu-DOTATATE for midgut neuroendocrine tumours.N Engl J Med. 2017; 376: 125-135
- 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.Lancet Oncol. 2021; 22: 1752-1763
- Patients resistant against PSMA-targeting α-radiation therapy often harbor mutations in DNA damage-repair-associated genes.J Nucl Med. 2020; 61: 683-688
- Development of targeted alpha particle therapy for solid tumors.Molecules. 2019; 24: 4314
- Peptide receptor radionuclide therapy of neuroendocrine tumors.Semin Nucl Med. 2020; 50: 447-464
- Prognostic value of 18F-FDG PET/CT in a large cohort of patients with advanced metastatic neuroendocrine neoplasms treated with peptide receptor radionuclide therapy.J Nucl Med. 2020; 61: 1560-1569
- Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance.Theranostics. 2017; 7: 1149-1158
- In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy.PLoS One. 2017; 12: e0181473
- DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy.PLoS One. 2014; 9: e88239
- Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors.Clin Cancer Res. 2008; 14: 3555-3561
- Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety.Eur J Nucl Med Mol Imaging. 2020; 47: 934-946
- Survival outcomes in metastatic gastroenteropancreatic neuroendocrine tumor patients receiving concomitant 225Ac-DOTATATE targeted alpha therapy and capecitabine: a real-world scenario management based long-term outcome study.J Nucl Med. 2022; https://doi.org/10.2967/jnumed.122.264043
- Dosing 225Ac-D122.264043. OTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity.Eur J Nucl Med Mol Imaging. 2021; 49: 54-63
- Subclinical hypothyroidism after 225Ac-DOTATATE therapy in a case of metastatic neuroendocrine tumor: unknown adverse effect of PRRT.Clin Nucl Med. 2022; 47: e184-e186
- Alpha before beta: exceptional response to first-line 225Ac-DOTATATE in a patient of metastatic neuroendocrine tumor with extensive skeletal involvement.Clin Nucl Med. 2022; 47: e156-e157
- Targeted alpha-emitter therapy with 212Pb-DOTAMTATE for the treatment of metastatic SSTR-expressing neuroendocrine tumors: first-in-human, dose-escalation clinical trial.J Nucl Med. 2022; 121 (jnumed): 263230
- Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) – a single-institution retrospective analysis.Eur J Nucl Med Mol Imaging. 2017; 45: 262-277
- Peptide receptor radionuclide therapy in Grade 3 neuroendocrine neoplasms: safety and survival analysis in 69 patients.J Nucl Med. 2019; 60: 377-385
- Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.Endocr Relat Cancer. 2019; 26: 227-239
- Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy.J Clin Oncol. 2004; 22: 2214-2232
- Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours.Eur J Nucl Med Mol Imaging. 2008; 35: 743-748
- 177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide.Eur J Nucl Med Mol Imaging. 2010; 37: 1869-1875
- Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours.Eur J Nucl Med Mol Imaging. 2011; 38: 302-311
- Pancreatic neuroendocrine tumor control: durable objective response to combination 177Lu-octreotate-capecitabine- temozolomide radiopeptide chemotherapy.Neuroendocrinology. 2016; 103: 432-439
- Concomitant 177Lu-DOTATATE and capecitabine therapy in patients with advanced neuroendocrine tumours: a long-term outcome, toxicity, survival, and quality-of-life study.Clin Nucl Med. 2017; 42: e457-e466
- Peptide receptor radionuclide therapy as first-line systemic treatment in advanced inoperable/metastatic neuroendocrine tumors.Clin Nucl Med. 2020; 45: e393-e399
- 177Lu-DOTATATE plus radiosensitizing capecitabine versus octreotide long-acting release as first-line systemic therapy in advanced grade 1 or 2 gastroenteropancreatic neuroendocrine tumors: a single-institution experience.JCO Glob Oncol. 2021; 7: 1167-1175
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
